By continuing to use our site, you consent to the processing of cookies, user data (location information, type and version of the OS, the type and version of the browser, the type of device and the resolution of its screen, the source of where the user came from, from which site or for what advertisement, language OS and Browser, which pages are opened and to which buttons the user presses, ip-address) for the purpose of site functioning, retargeting and statistical surveys and reviews. If you do not want your data to be processed, please leave the site.

The Voice of People With Breast Cancer

Education

Our Voices Blog

Clinical Trials in Canada: What’s currently being offered in breast cancer? - Metastatic

Title of Study: A Phase 3b study to assess the safety and efficacy of RIBOCICLIB in combination with LETROZOLE for the treatment of men and pre/postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer with no prior hormonal therapy for advanced disease

Patient Population: HR+ and HER2- locally advanced or metastatic breast cancer

Locations: Edmonton, Calgary, Vancouver, Halifax, Hamilton, Montreal, Regina, Saskatoon

Click HERE for more information.


Title of Study: A randomized, double-blind, Phase 3 study of PEMBROLIZUMAB + CHEMOTHERAPY versus PLACEBO + CHEMOTHERAPY for previously untreated locally recurrent inoperable or metastatic triple negative breast cancer

Patient Population: Triple negative locally recurrent inoperable or metastatic breast cancer

Locations: Toronto, Ottawa, Montreal

Click HERE for more information.


Title of Study: A Phase 2 randomized, double-blinded, controlled study of TUCATINIB versus PLACEBO in combination with CAPECITABINE and TRASTUZUMAB in patients with pretreated unresectable locally advanced or metastatic HER2 positive breast cancer

Patient Population: HER2+ locally advanced or metastatic breast cancer

Locations: Edmonton, Calgary, St. John’s, Halifax, Toronto, Québec, Montreal, Regina, Saskatoon

Click HERE for more information.


Title of Study: A Phase 2 study of ABEMACICLIB in patients with brain metastases secondary to hormone receptor positive breast cancer

Patient Population: HR+ metastatic breast cancer

Locations: Ottawa

Click HERE for more information.


Title of Study: A Phase 3, randomised, double-blind, placebo-controlled study of ATEZOLIZUMAB in combination with PACLITAXEL compared with PLACEBO with PACLITAXEL for patients with previously untreated inoperable locally advanced or metastatic triple negative breast cancer.

Patient Population: locally advanced or metastatic triple negative breast cancer

Locations: Edmonton, Calgary, Kingston, London, Toronto, Montreal, Quebec City, Sherbrooke

Click HERE for more information.

Photo by rawpixel.com on Unsplash

Related posts


The views and experiences expressed through personal stories on Our Voices Blog are those of the authors and their lived experiences. They do not necessarily reflect the position of the Canadian Breast Cancer Network. The information provided has not been medically reviewed and is not intended to be a substitute for professional medical advice. Always seek the guidance of your healthcare team when considering your treatment plans and goals.